Results 151 to 160 of about 191,796 (284)

Model‐Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 322-335, February 2026.
Model‐informed drug development (MIDD) played a crucial role in the successful development and regulatory approval of daprodustat, a novel oral hypoxia‐inducible factor prolyl hydroxylase (HIF‐PHI) inhibitor aimed at treating anemia in chronic kidney disease patients.
Kelly M. Mahar   +6 more
wiley   +1 more source

Rethinking Statin Dosage in Coronary Disease

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
It is widely acknowledged that a sufficient statin dose is important in the management of symptomatic coronary disease, along with weight reduction and appropriate antithrombotic, blood pressure, and diabetes pharmacotherapy. Mid‐range statin doses have been shown to achieve the maximum improvements in total mortality and have the advantage of greater ...
Simon B. Dimmitt   +3 more
wiley   +1 more source

Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis [PDF]

open access: bronze, 2010
C. Combescure   +9 more
openalex   +1 more source

High Rates of Defect Closure After Resection of Large Nonpedunculated Colorectal Lesions Using a Through‐The‐Scope Clip With Anchor Prongs

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Prophylactic complete closure of mucosal defects after resection of gastrointestinal lesions is key to reducing delayed bleeding, but complete closure for large defects can be challenging with conventional through‐the‐scope clips (TTSC).
Daniel von Renteln   +11 more
wiley   +1 more source

Clopidogrel and Postoperative Bleeding [PDF]

open access: bronze, 2004
Piet W. Boonstra, Wim van Oeveren
openalex   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy